<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049825</url>
  </required_header>
  <id_info>
    <org_study_id>317-102-00007</org_study_id>
    <nct_id>NCT04049825</nct_id>
  </id_info>
  <brief_title>A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL</brief_title>
  <official_title>A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Trial to Evaluate the Safety of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and
      rituximab in patients with r/r DLBCL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>23days</time_frame>
    <description>The tolerability of OPB-111077 in combination with bendamustine and rituximab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse events(AEs)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Safety of OPB-111077 in combination with bendamustine and rituximab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy based on International working group(IWG) Lugano response criteria for Non Hodgkin's lymphoma ( (NHL) (2014))</measure>
    <time_frame>Last dose of study drug (up to 3 years)</time_frame>
    <description>Percentage of Participants with Complete Response based on International working group(IWG) Lugano response criteria for Non Hodgkin's lymphoma ( (NHL) (2014))
Percentage of Participants with Complete Response and Partial Response based on International working group(IWG) Lugano response criteria for Non Hodgkin's lymphoma ( (NHL) (2014))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Relapsed or Refractory Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of OPB-111077 in the first cohort will be 200 mg/day, increasing as appropriate to 400 mg/day in the second cohort and then to 600 mg/day in the third cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 days on and 3days off of 21-day cycles of OPB-111077 Day 1 of 21-days cycles of rituximab Day 2 and 3 of 21-day cycles of bendamustine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPB-111077</intervention_name>
    <description>OPB-111077+bendamustine</description>
    <arm_group_label>Dose Escalation Stage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPB-111077</intervention_name>
    <description>OPB-111077+rituximab+bendamustine</description>
    <arm_group_label>Dose Expansion Stage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a definite diagnosis of Diffuse large B-cell lymphoma(DLBCL)

          -  Patients who have received at least initial standard treatment

          -  Patients with measurable lesions (based on International Working Group [IWG] 2014
             criteria)

          -  Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS)
             score of 0 or 1

        &lt;Only for dose-expansion stage&gt;

          -  Patients who are pathologically diagnosed as CD20 positive lymphoma

          -  Patients who have a history of being treated with 1 to 3 regimens of previous
             chemotherapy for the underlying disease

        Exclusion Criteria:

          -  Patients who are candidates for autologous or allogeneic hematopoietic stem cell
             transplantation

          -  Patients who were refractory to initial standard treatment

          -  Patients who have a history of bendamustine administration and are intolerant to
             bendamustine

          -  Patients with central nervous system (CNS) involvement of lymphoma or with a history
             of CNS involvement of lymphoma

          -  Patients diagnosed with DLBCL transformed from low-grade B-cell non-Hodgkin's lymphoma
             (NHL)

        &lt;Only for dose-expansion stage&gt;

        - Patients who have a history of rituximab administration and are intolerant to rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Yamagata University Hospital</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

